Driehaus Capital CRMD Position
ExitedDriehaus Capital exited their position in CorMedix Inc. (CRMD) in Q3 2025, after holding the stock for 2 quarters.
The position was first reported in Q2 2025 and has been tracked across 2 quarterly 13F filings.
2 other tracked funds also hold CRMD.
There is an upcoming Phase 3 readout for (taurolidine and heparin) catheter lock solution in 290 days (Jan 31, 2027), making the timing of Driehaus's position particularly relevant.
Short interest stands at 20.2% of float with 9.6 days to cover, indicating significant bearish positioning against the stock.
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Full company profile →Short Interest
20.2%
9.6 days to cover
Driehaus Capital CRMD Position History
Frequently Asked Questions
Does Driehaus Capital own CRMD?
No. Driehaus Capital exited their position in CorMedix Inc. (CRMD) in Q3 2025. They previously held the stock for 2 quarters.
How many hedge funds own CRMD?
2 specialist biotech hedge funds currently hold CRMD, including Deep Track Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy CRMD?
Driehaus Capital's position in CRMD was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's CRMD position increasing or decreasing?
Driehaus Capital completely exited their CRMD position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CRMDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →